Alvotech Targets Chinese Biosimilars With Yangtze River Deal
Exclusive Partnership Covers Eight Biosimilar Candidates In China
Alvotech has struck a major deal with Yangtze River Pharmaceutical that will allow eight of the biosimilars developer’s products to be commercialized in China.
You may also be interested in...
Alvotech’s Wessman Sets Out Next Steps On Biosimilars Journey
Alvotech ended 2021 by revealing major plans for a SPAC merger that will provide fresh impetus for the biosimilars specialist with an injection of almost $500m in funding. In the first part of an exclusive two-part interview, founder and chairman Robert Wessman tells Generics Bulletin how the firm plans to move forward following the transaction.
Will AbbVie’s Trade Secrets Suit Against Alvotech Follow Path Of Similar Biotech Battles?
AbbVie claims a former employee took Humira manufacturing process know-how to Alvotech. Settlement is likely as Alvotech does not want to delay development of its biosimilar and AbbVie doses not want to disclose its trade secrets in court.
Alvotech Completes $100m Private Placement
Alvotech has completed a $100m private placement after concluding a second found of funding worth $35m. The move comes as the company prepares to commercialize its portfolio of biosimilars through a series of partnerships.